AIDS: International AIDS Conference
The father-and-daughter team of William and Erika Check will be blogging from the XVI International AIDS Conference here from 13-18 August. Check back for updates.
William Check is also writing for the AIDS conference newspaper, The Daily Voice, this week. But his views expressed here are entirely personal; he is not a spokesperson for the conference.
Erika Check is Nature's Biomedical Correspondent, and is usually based in San Francisco.
Comments
India and South Africa have banned isoniazid preventive therapy because of fears that over-use may lead to drug resistance, Chaisson says, though he adds there is little evidence that this is really a problem.”
" Richard Chaisson, of Johns Hopkins University in Baltimore, Maryland, who led the research, is calling on governments and funding bodies to provide such integrated treatments to patients right away.”
One group was given antiretroviral drugs to supress the HIV virus. Another group was treated with an anti-TB drug called isoniazid, which costs less than US$1 for a full course. A third group was given both.
DO readers have any comments on the ethics of such a treatment allocation? What are Chaisson's comments that 'there is little evidence that INH resistance is a problem' based on?
Posted by: Anuradha Bose | August 23, 2006 03:59 PM
Actually isoniazid should be banned in some Eastern European countries where it is used in tuberculosis drug treatment and in prevention. Local studies are showing a increased resistance of Koch microbe on usual treatments like Isoniazide and Riphampicine.
Posted by: MartinL | July 23, 2007 08:45 PM